LRI Investments’s Cidara Therapeutics CDTX Stock Holding History

LRI Investments’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-55	Closed	-$5.27K	–	1361
2025 Q3	$5.27K	Buy	+55	New	+$3.51K	﹤0.01%	1038

Other funds holding CDTX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

LRI Investments's CDTX Position: Q4 2025 in Review

LRI Investments sold out of Cidara Therapeutics (CDTX) in Q4 2025, closing a stake of 55 shares — an estimated $5.27K sold.

LRI Investments first reported a position in CDTX in Q3 2025 and held it in 1 quarter. The position peaked at $5.27K in Q3 2025. 255 funds tracked by Wall St. Rank hold CDTX as of Q4 2025.

LRI Investments reported no remaining Cidara Therapeutics position as of Q4 2025 after selling out during the quarter.
LRI Investments sold 55 Cidara Therapeutics shares in Q4 2025, an estimated $5.27K.
LRI Investments first reported a position in Cidara Therapeutics in Q3 2025 and held it in 1 quarter.
LRI Investments's Cidara Therapeutics position peaked at $5.27K in Q3 2025.
255 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2025.

Based on LRI Investments's 13F filing for Q4 2025, filed 4 Feb 2026.